@KronzerMD @jeffsparks on association of respiratory diseases with incident RA. Upper airway diseases (sinusitis, pharyngitis) seem to associate even more strongly than asthma/COPD. Abstr#564 #ACR21 @RheumNow https://t.co/HvoBOs3OOF

Dr Mahajan on lung disease in early RA. Common, airway disease in 60%, parenchymal disease in 30%. But minimal/no progression over 1 year which is reassuring. Abstr#574 #ACR21 @RheumNow https://t.co/s9r06MSStF

MUC5B and RA-ILD. Dr McDermott @jeffsparks show that MUC5B is associated with RA-ILD, older age at RA diagnosis, and ILD within 5 years of RA onset. Is this a different disease to other RA or modulation by the promotor variant? Abstr#0576 #ACR21 @RheumNow https://t.co/r2fQqxVY6N

And here is ORAL-Surveillance, small increase in MACE and malignancy with tofacitinib vs TNFi. 1 extra MACE per 319-567 patient years, 1 extra malignancy per 275 patient years. Abstr#0831 #ACR21 @RheumNow https://t.co/wMJnspTTBy

For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx

Dr. Thomas reviews risk for progression to RA 👉+ACPA (9% risk) 👉1st degree relative 3-9X risk 👉70% risk in 5 years of both are true!👈 #ACR21 @rheumnow https://t.co/y5eUyacBFT

An important message from Dr Ranjeny Thomas on #RA #disease control: "Patients can have a significant impact on the control of their disease, and the interventions we recommend need to be personalised to their resilience ability." #ACR21 @RheumNow https://t.co/h63uz5kfU8

Booking regular clinic visits for controlled RA pts - can we be more efficient? 12m RCT Self-monitoring app, supported self-initiated care only one scheduled follow-up visit controlled RA pts DAS28/pt satisfaction same visits/y: 1.7 vs 3.0 @reade_020 #ACR21 ABST0830 @RheumNow https://t.co/600XTKo9GM

Risks for RA: - chromosome 6 has HLA risk genes encoding HLA-I and -II - HLA-DRB1 *04:01 and *04:04 stonrgly assc w/ RA in white Americans/Europeans - the Shared epitope increase risk for RA & severe disease; high assc with ACPA+ Protective➡️HLA-DRB1*13:01 @rheumnow #ACR21 2/2